Fig. 3: Immunogenicity in rhesus macaques. | Nature Communications

Fig. 3: Immunogenicity in rhesus macaques.

From: Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection

Fig. 3

A Schematic of SARS-CoV-2 vaccine evaluation and challenge in rhesus macaques. Orange circles represent ChAd immunization (5 × 1011 VP), blue squares represent SAM vaccination at varying doses and black circle represents challenge with SARS-CoV-2 virus. N = 5/group. B Spike S1 IgG endpoint titers, geometric mean (annotated), and geometric SD. LOD = 50, samples below LOD set to ½ LOD. C Spike-specific T-cell responses assessed by overnight IFNγ ELISpot at specified timepoint post immunization. Mean (annotated) ± SEM. D IL-4 vs IFNγ ELISpot of PBMCs assessed 1-week post boost immunization. Individual animal values (n = 5/group). Diagonal line represents unity line. Positive control stimulated wells were too numerous to count accurately. E Pseudovirus neutralization titers assessed in sera at specified timepoint post immunization. LOD = 50, samples <LOD set to ½ LOD. Geometric mean (annotated) and geometric SD. HCS = human convalescent serum assessed by same assay. C = PBS control injected animals assessed 8 weeks post injection. F Live virus micro-neutralizing titer at specified timepoint post immunization and post SARS-CoV-2 challenge, geometric mean (annotated), and geometric SD. LOD = 20, samples below LOD set to ½ LOD.

Back to article page